Last $10.29 USD
Change Today -0.06 / -0.58%
Volume 616.7K
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$10.42
Previous Close
$10.35
Day High
$10.68
Day Low
$10.25
52 Week High
02/24/14 - $17.80
52 Week Low
10/17/14 - $7.70
Market Cap
884.3M
Average Volume 10 Days
951.7K
EPS TTM
$-0.97
Shares Outstanding
85.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

307 Employees
Last Reported Date: 08/28/14
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $544.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $245.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $432.4K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $377.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $297.3K
Compensation as of Fiscal Year 2014.

immunogen inc (IMGN) Key Developments

Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents

Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported total revenues of $13,203,000 compared to $17,218,000 a year ago. Loss from operations was $21,910,000 compared to $11,337,000 a year ago. Net loss was $22,282,000 or $0.26 per basic and diluted share compared to $11,226,000 or $0.13 per basic and diluted share a year ago. Cash used in operations was $18.9 million compared with $23.6 million in the same period in last year. Capital expenditures were $1.7 million and $0.6 million for the first three months of fiscal year 2015 and fiscal year 2014, respectively. The company’s fiscal year 2015 financial guidance remains unchanged from that issued in August 2014. The company expects its revenues to be between $100 million and $105 million and net loss to be between $60 million and $65 million. Cash used in operations to be between $55 million and $60 million and its capital expenditures to be between $7 million and $9 million.

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. announced that Dr. James J. O'Leary, Vice President and Chief Medical Officer of the company of his intention to leave the company's employ in mid-October 2014 for personal reasons. His responsibilities will be assumed by Dr. Charles Q. Morris, Executive Vice President and Chief Development Officer, to whom Dr. O'Leary currently reports.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $10.29 USD -0.06

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.94 EUR -0.009
BioInvent International AB kr2.81 SEK -0.07
Genmab A/S kr295.70 DKK -0.20
MorphoSys AG €78.87 EUR -0.55
Seattle Genetics Inc $36.44 USD -0.35
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 15.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.